Sumitomo bets on Roivant to solve its patent expiry woes
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
GE Healthcare float sunk in favour of Danaher deal
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
Pfizer turns to private equity for second round of pipeline divestments
Bain Capital’s investment in a clutch of Pfizer neurology projects raises the question of what interest private equity might have in financing risky biopharma research…
Midatech hopes to find golden touch with new focus
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Momenta starts countdown to biosimilars exit
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
